University of California, San Francisco: Carcinoma trials

The registry lists 18 Carcinoma studies with University of California, San Francisco as lead sponsor. 0 are open to participants now and 7 have results posted.

Phase 1 7Phase 2 6No phase 6(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• 177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate CancerCompletedNCT03805594Phase 1Results posted
• Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine CarcinomasCompletedNCT03136055Phase 2Results posted
• Selinexor in Treating Patients With Abiraterone Acetate and/or Enzalutamide Refractory Metastatic Castration-Resistant Prostate CancerTerminatedNCT02215161Phase 2Results posted
• TACE Using Doxorubicin-eluting Beads for Patients With HCC and Marginal Hepatic ReserveTerminatedNCT02147301Not applicableResults posted
• Phase II Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular CarcinomaCompletedNCT01687673Phase 2Results posted
• Yttrium-90 Radioembolization With Glass Microspheres (TheraSphere) for Patients With Hepatocellular CarcinomaTerminatedNCT01290523Not applicableResults posted
• Tamoxifen or Letrozole in Treating Women With Ductal Carcinoma in SituCompletedNCT00290745Phase 1/2Results posted
• Incorporating ePrognosis for the Encouragement of Smarter Screening for Breast and Colorectal Cancer in Older AdultsCompletedNCT05021172Not applicable
• T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast CancerCompletedNCT03554044Phase 1
• Talimogene Laherparepvec in Treating Patients With Non-Muscle Invasive Bladder Transitional Cell CarcinomaWithdrawnNCT03430687Phase 1
• Radiation Therapy and Pembrolizumab in Treating Patients With Localized Urothelial Bladder CancerWithdrawnNCT03419130Phase 2
• Concordance of Two Endoscopic Procedures for Diagnosis of Carcinoma of the Upper Aerodigestive TractWithdrawnNCT01175499Not applicable
• Temsirolimus and Sorafenib in Advanced Hepatocellular CarcinomaCompletedNCT01008917Phase 1
• Contrast-Enhanced MRI for the Characterization of Ductal Carcinoma in Situ (DCIS)CompletedNCT00804128
• Vorinostat in Treating Women With Ductal Carcinoma in Situ of the BreastCompletedNCT00788112Phase 1
• Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic AnemiaCompletedNCT00513175
• Effect of Fluvastatin on Biomarkers in Women Who Are Undergoing Surgery for Ductal Carcinoma In Situ or Stage I Breast CancerCompletedNCT00416403Phase 2
• Sorafenib and RAD001 Renal Cell CarcinomaCompletedNCT00384969Phase 1